Evotec Gets $15M Up Front in Bayer Endometriosis Pact
Monday, October 1, 2012
Evotec AG is pocketing €12 million (US$15.5 million) up front and could receive up to €580 million more in preclinical, clinical and commercial milestones from a drug discovery alliance focused on endometriosis with Bayer Pharma AG.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.